Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/20042
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHamblin, Peter S-
dc.contributor.authorSheehan, Penelope M-
dc.contributor.authorAllan, Carolyn-
dc.contributor.authorHoulihan, Christine A-
dc.contributor.authorLu, Zhong X-
dc.contributor.authorForehan, Simon P-
dc.contributor.authorTopliss, Duncan J-
dc.contributor.authorGilfillan, Christopher-
dc.contributor.authorKrishnamurthy, Bala-
dc.contributor.authorRenouf, Debra-
dc.contributor.authorSztal-Mazer, Shoshana-
dc.contributor.authorVaradarajan, Suresh-
dc.date2018-12-18-
dc.date.accessioned2019-01-02T01:15:10Z-
dc.date.available2019-01-02T01:15:10Z-
dc.date.issued2018-12-18-
dc.identifier.citationInternal medicine journal 2018; online first: 18 December-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/20042-
dc.description.abstractInterest in potential adverse outcomes associated with maternal subclinical hypothyroidism (normal Free T4, elevated TSH) has increased significantly over recent years. In turn, the frequency of maternal thyroid function testing has risen, despite universal thyroid function screening not being recommended, leading to a marked increase in referrals to obstetric endocrinology clinics. In 2017 the American Thyroid Association (ATA) revised their diagnostic and management guidelines. While welcome, these new guidelines contain recommendations which may cause confusion in clinical practice. To ensure uniform practice in the diagnosis and management of subclinical hypothyroidism in pregnancy across all Melbourne Public Hospitals. Consensus was achieved and the guidelines were endorsed by the Council of the Endocrine Society of Australia. Trimester and assay specific TSH reference intervals derived from healthy local populations should be used, where available. When unavailable, a TSH cut-off of 4 mU/L (replacing the previously recommended 2.5 mU/L) should be used to initiate treatment, irrespective of thyroid autoantibody status. The recommended starting dose of levothyroxine is 50 ug daily, with a therapeutic TSH target of 0.1 mU/L to 2.5 mU/L. Levothyroxine should generally be ceased after delivery, with some exceptions. Hospitals will ensure smooth transfer of care back to the woman's general practitioner with clear documentation of pregnancy thyroid management and a recommended plan for follow-up. Fewer women will be classified as having subclinical hypothyroidism during pregnancy, which is likely to lead to reductions in emotional stress, hospital visits, repeated blood tests and financial costs. Uniform clinical practice will occur across Melbourne. This article is protected by copyright. All rights reserved.-
dc.language.isoeng-
dc.subjectHypothyroidism-
dc.subjectPregnancy-
dc.subjectSubclinical hypothyroidism-
dc.titleSubclinical Hypothyroidism During Pregnancy: The Melbourne Public Hospitals Consensus.-
dc.typeJournal Article-
dc.identifier.journaltitleInternal medicine journal-
dc.identifier.affiliationPeninsula Clinical School, Monash University, Frankston, Victoria, Australiaen
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Eastern Health, Box Hill, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Eastern Clinical School, Monash University, Box Hill, Victoria, Australiaen
dc.identifier.affiliationWerribee Mercy Hospital, 300 Princes Highway, Werribee, Victoria, Australiaen
dc.identifier.affiliationSt Vincents Institute of Medical Research, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australiaen
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Peninsula Health, Frankston, Victoria, Australiaen
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Western Health, Sunshine Hospital, 176 Furlong Road, St Albans 3021en
dc.identifier.affiliationDepartment of Medicine - Western Precinct, The University of Melbourne, St Albans, VIC, 3021en
dc.identifier.affiliationPregnancy Research Centre, Royal Women's Hospital, Parkville, Victoria, Australiaen
dc.identifier.affiliationUniversity of Melbourne Department of Obstetrics & Gynaecology, Royal Women's Hospital, Parkville, Victoria, Australiaen
dc.identifier.affiliationEndocrine Services in Pregnancy, Monash Health, Clayton, Victoria, Australiaen
dc.identifier.affiliationHudson Institute of Medical Research Clayton, Victoria, Australiaen
dc.identifier.affiliationMercy Hospital for Women, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Chemical Pathology, Melbourne Pathology, Collingwood, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Monash University, Clayton, Victoria, Australiaen
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, The Alfred, Commercial Road, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Central Clinical School, Monash University, The Alfred, Commercial Road Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Northern Health, Epping, Victoria, Australia-
dc.identifier.doi10.1111/imj.14210-
dc.identifier.orcid0000-0002-6280-865X-
dc.identifier.pubmedid30561039-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.